Key Highlights
- Armata Pharmaceuticals received FDA Breakthrough Therapy Designation for intravenous AP-SA02.
- AP-SA02 is being developed as an adjunctive therapy for complicated Staphylococcus aureus bacteremia (MSSA or MRSA).
- The designation builds on existing QIDP and Fast Track designations.
- It follows positive Phase 1b/2a diSArm study results showing accelerated clinical cure and zero relapses through Day 28.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced the FDA granted Breakthrough Therapy designation to intravenous AP-SA02 as an adjunctive therapy for complicated Staphylococcus aureus bacteremia, covering both MSSA and MRSA.
What Happened
The designation builds on existing QIDP and Fast Track designations, following positive Phase 1b/2a diSArm study results that demonstrated favorable safety, accelerated clinical cure, zero relapses through Day 28, and encouraging biomarker signals.
Market Reaction
The disclosed information does not include stock price or trading data for Armata Pharmaceuticals following the Breakthrough Therapy designation.
Outlook
The Breakthrough Therapy designation is intended to support more frequent FDA interaction and a potentially expedited development path for AP-SA02, representing the next relevant regulatory tailwind for the program.
FAQs
Q: What designation did Armata Pharmaceuticals receive?
A: FDA Breakthrough Therapy designation for AP-SA02, as an adjunctive therapy for complicated Staphylococcus aureus bacteremia.
Q: What other designations does AP-SA02 hold?
A: QIDP and Fast Track designations.
Q: What did the Phase 1b/2a diSArm study show?
A: Favorable safety, accelerated clinical cure, zero relapses through Day 28, and encouraging biomarker signals.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.